Statements (104)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Incyte_Corporation
gptkb:Ariad_Pharmaceuticals |
| gptkbp:activities |
tyrosine kinase inhibitor
|
| gptkbp:approves |
gptkb:chronic_myeloid_leukemia
gptkb:healthcare_organization |
| gptkbp:availability |
prescription only
|
| gptkbp:category |
gptkb:D
not recommended |
| gptkbp:clinical_trial |
Phase 2
Phase 3 targeted therapy Pivotal trial for ALL Pivotal trial for CML |
| gptkbp:contraindication |
severe hepatic impairment
concurrent use of strong CY P3 A4 inducers concurrent use of strong CY P3 A4 inhibitors hypersensitivity to ponatinib |
| gptkbp:discontinued |
gptkb:battle
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:effective_date |
2012-12-14
|
| gptkbp:has_ability |
15 mg
30 mg 45 mg |
| gptkbp:healthcare |
gptkb:2012
|
| https://www.w3.org/2000/01/rdf-schema#label |
Iclusig
|
| gptkbp:indication |
gptkb:Philadelphia_chromosome-positive_leukemia
|
| gptkbp:ingredients |
gptkb:ponatinib
C29 H31 N7 O2 S C24 H27 N7 O2 S |
| gptkbp:interacts_with |
gptkb:warfarin
CY P3 A4 inducers CY P3 A4 inhibitors |
| gptkbp:invention |
2027-12-14
|
| gptkbp:is_atype_of |
L01 X E30
|
| gptkbp:is_monitored_by |
blood pressure
liver function tests blood counts lipase levels |
| gptkbp:is_used_for |
treatment of chronic myeloid leukemia
treatment of acute lymphoblastic leukemia |
| gptkbp:legal_issue |
prescription only
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Ariad_Pharmaceuticals
|
| gptkbp:market |
currently marketed
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Iclusig gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:pharmacokinetics |
metabolized by liver
bioavailability 100% half-life 24 hours inhibits BCR-ABL tyrosine kinase inhibits FGFR inhibits PDGFR inhibits VEGFR |
| gptkbp:population |
adults
|
| gptkbp:previous_name |
gptkb:ponatinib
|
| gptkbp:price |
varies by region
varies by country |
| gptkbp:requires |
available online
|
| gptkbp:safety_features |
risk of infection
risk of heart failure risk of bleeding risk of arterial thrombosis risk of hepatotoxicity |
| gptkbp:side_effect |
gptkb:fandom
fatigue headache muscle pain nausea hypertension weight loss fever vomiting diarrhea bleeding joint pain dry skin cardiovascular events hypokalemia thrombosis skin rash thrombocytopenia infection risk hepatotoxicity pancreatitis neutropenia eye problems elevated liver enzymes hypophosphatemia hyperuricemia hypomagnesemia myelosuppression elevated bilirubin |
| gptkbp:storage |
room temperature
|
| gptkbp:targets |
gptkb:BCR-ABL_fusion_protein
gptkb:KIT_mutations FL T3 mutations PDGFR mutations |
| gptkbp:type_of |
943127-13-0
|
| gptkbp:type_of_care |
important for treatment efficacy
|